Partner David Berl will speak at the upcoming Hatch-Waxman and BPCIA Essential Proficiency Series on October 13th at 2:30pm. The series is a virtual three-week program designed to provide new lawyers and executives in the life sciences industry with a solid foundation for understanding Hatch-Waxman and BPCIA litigation and regulation. David’s panel, “Small and Large Molecule Drug Patents and Other Related IP Protections and Mechanisms,” will address the patenting process for drugs and biologics, strategies for patent protection, PTE and PTA synopsis, and distinguishing the patenting process for drugs from that for biologics.

David is Co-Chair of the firm’s Patent Litigation practice and focuses principally in the biotechnology, pharmaceutical, and energy fields. David has served as lead counsel in numerous biotechnology and pharmaceutical patent trials, in appellate proceedings in the Court of Appeals for the Federal Circuit, and in inter partes review proceedings before the PTO. He regularly serves as lead counsel to major corporations in significant patent litigations.

Click here to learn more and register for the conference.